Platinum-Free Interval Linked With Survival in Recurrent Ovarian Cancer
The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer, according to a study published online in Gynecologic Oncology (online November 15, 2017; doi: 10.1016/j.ygyno.2017.11.008).
The finding stems from an investigation of treatment approaches and outcomes for 2369 women aged 66 years and older with epithelial ovarian cancer. Study participants underwent surgery and platinum-based chemotherapy and developed a recurrence more than 3 months after finishing adjuvant therapy.
Women with a platinum-free interval of 6 months or less had a median survival of 13 months, according to the study. Those with a platinum-free interval between 7 and 12 months had a median survival of 18 months, and women whose platinum-free interval lasted 1 year or more has a median survival of 27 months.
The study, which also looked at treatment choices, identified a wide variation in regimens and, for many women, a lack of guideline-based recommendations.
Among women with a platinum-free interval of 6 months or less, 28.2% received platinum-based combination therapy, 5.2% received single-agent platinum, and 66.6% received nonplatinum therapy. Among women with a platinum-free interval between 7 and 12 months, 39.7% received platinum-based combination therapy, 12.4% received single-agent platinum, and 47.9% received nonplatinum therapy. The corresponding rates of those treatments for women whose platinum-free interval lasted 1 year or more were 57.6%, 13.2%, and 29.3%, respectively.
“For all three groups,” researchers reported, “platinum combination therapy was associated with decreased risk of death compared to nonplatinum based therapy.”—Jolynn Tumolo